U.S. Stock SEC Cash-Flow Directory / Healthcare
ADPTAccumulate
Adaptive Biotechnologies Corporation Common Stock · Biological Products, (No Diagnostic Substances)
Normal Volatility & Next-Quarter Cash-Flow Follow-Through
Historical swing check: Adaptive Biotechnologies Corporation Common Stock pulled back 39.4% from peak to trough over the past year — ask whether your position size stays comfortable through a similar dip.
- Does ADPT's current valuation leave reasonable upside relative to its $7.7M SEC Free Cash Flow?
- How large would a position in ADPT make my overall Healthcare concentration?
- What change in SEC cash flow or trend episodes would cause us to trim or exit?
Official U.S. SEC EDGAR Filing Snapshot (ADPT)
Period Ended 2026-09-30 · Filed 2026-11-04See All 36 Healthcare Stocks Rated Accumulate Right Now
Every TFE Accumulate stock requires verified positive SEC Free Cash Flow, constructive multi-episode trend durability, and S&P 500 relative strength. Unlock the full 254-stock Accumulate roster, full 2,400+ stock Screener, and personal Watchlist.
Research Disclosure: Standardized impersonal model publication for research use only — not personalized investment advice and not a brokerage site. Verify all filings and live quotes independently before making investment decisions.